Caribou Biosciences (CRBU) Clinical Data Misrepresentation Case

• $CRBU investors filed a lawsuit against Caribou Biosciences for misleading them about the safety, efficacy, and commercial prospects of their lead product, CB-010.

• On June 2, 2024, Caribou presented updated Phase 1 clinical trial data for CB-010, which revealed lower-than-expected response rates and progression-free survival. Following this, $CRBU dropped by 25.52%.

• $CRBU investors can join this case to be notified about potential recovery.

Case Details:

Between July 14, 2023, and July 16, 2024, Caribou Biosciences promoted CB-010, an allogeneic anti-CD19 CAR-T cell therapy, as a safer and more effective alternative to traditional CAR-T treatments. They claimed CB-010 could rival or surpass existing therapies in safety, effectiveness, and durability.

However, at June 2, 2024, ASCO event, Caribou shared Phase 1 trial results showing a 36% complete response rate—significantly lower than the 65-66% rates of competing therapies. The trial also revealed shorter progression-free survival for patients using CB-010.

On July 16, 2024, Caribou announced a 12% workforce reduction and the suspension of its CAR-NK research program to save funds. These developments left investors questioning the company’s future.

Following this $CRBU dropped by 25.52%

Based on these events, $CRBU investors filed a lawsuit against Caribou Biosciences, claiming the company:

• It misled investors about CB-010’s clinical trial results and ability to compete with approved therapies.

• It failed to disclose financial challenges and risks tied to its CAR-NK research platform.

Investors believe Caribou overstated the potential of CB-010 and concealed financial instability.